Limits...
Bisoprolol in the treatment of chronic heart failure.

de Groote P, Ennezat PV, Mouquet F - Vasc Health Risk Manag (2007)

Bottom Line: Bisoprolol fumarate is a highly selective beta-1 receptor blocker.There was no difference in morbidity and mortality between sub-groups of patients receiving first bisoprolol or enalapril.Bisoprolol fumarate is a selective beta-1 receptor blocker that significantly reduced morbidity and mortality in stable CHF patients.

View Article: PubMed Central - PubMed

Affiliation: Service de Cardiologie C, Hôpital Cardiologique, CHRU de Lille, 59037 Lille Cedex, France. pdegroote@chru-lille.fr

ABSTRACT
Bisoprolol fumarate is a highly selective beta-1 receptor blocker. Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients. The CIBIS trial enrolled 641 patients and demonstrated the good tolerability of bisoprolol in a large CHF population, without evidence for any harmful effect. The CIBIS-II study was the first large randomized, double-blind, placebo-controlled study demonstrating in 2647 patients a dramatic reduction in mortality with a beta-blocking agent in CHF patients. CIBIS-III demonstrated in 1010 patients the equivalence of 2 different therapeutic strategies in de novo CHF patients. There was no difference in morbidity and mortality between sub-groups of patients receiving first bisoprolol or enalapril. These three trials also demonstrated the good tolerability of bisoprolol fumarate. Other studies were either limited in number of patients or not randomized. However, these studies confirmed the good tolerability of bisoprolol in CHF patients, even in elderly population. Bisoprolol fumarate is a selective beta-1 receptor blocker that significantly reduced morbidity and mortality in stable CHF patients. Bisoprolol is well tolerated with few significant side effects in different large trials.

Show MeSH

Related in: MedlinePlus

Study design of CIBIS-III. Double titration with monotherapy and combination phases for each arm, bisoprolol-first and enalapril-first.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2291328&req=5

fig3: Study design of CIBIS-III. Double titration with monotherapy and combination phases for each arm, bisoprolol-first and enalapril-first.

Mentions: CIBIS-III was a multicenter, prospective, randomized, open label, blinded end-point evaluation study, with 2 parallel groups (Figure 3). Inclusion criteria were different from the previous CIBIS studies. Eligible patients were patients older than 65 years, in NYHA class II or III, with a LVEF ≤35% and of course receiving neither ACEI nor beta-blocker. All patients were clinically stable for at least 7 days before the inclusion.


Bisoprolol in the treatment of chronic heart failure.

de Groote P, Ennezat PV, Mouquet F - Vasc Health Risk Manag (2007)

Study design of CIBIS-III. Double titration with monotherapy and combination phases for each arm, bisoprolol-first and enalapril-first.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2291328&req=5

fig3: Study design of CIBIS-III. Double titration with monotherapy and combination phases for each arm, bisoprolol-first and enalapril-first.
Mentions: CIBIS-III was a multicenter, prospective, randomized, open label, blinded end-point evaluation study, with 2 parallel groups (Figure 3). Inclusion criteria were different from the previous CIBIS studies. Eligible patients were patients older than 65 years, in NYHA class II or III, with a LVEF ≤35% and of course receiving neither ACEI nor beta-blocker. All patients were clinically stable for at least 7 days before the inclusion.

Bottom Line: Bisoprolol fumarate is a highly selective beta-1 receptor blocker.There was no difference in morbidity and mortality between sub-groups of patients receiving first bisoprolol or enalapril.Bisoprolol fumarate is a selective beta-1 receptor blocker that significantly reduced morbidity and mortality in stable CHF patients.

View Article: PubMed Central - PubMed

Affiliation: Service de Cardiologie C, Hôpital Cardiologique, CHRU de Lille, 59037 Lille Cedex, France. pdegroote@chru-lille.fr

ABSTRACT
Bisoprolol fumarate is a highly selective beta-1 receptor blocker. Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients. The CIBIS trial enrolled 641 patients and demonstrated the good tolerability of bisoprolol in a large CHF population, without evidence for any harmful effect. The CIBIS-II study was the first large randomized, double-blind, placebo-controlled study demonstrating in 2647 patients a dramatic reduction in mortality with a beta-blocking agent in CHF patients. CIBIS-III demonstrated in 1010 patients the equivalence of 2 different therapeutic strategies in de novo CHF patients. There was no difference in morbidity and mortality between sub-groups of patients receiving first bisoprolol or enalapril. These three trials also demonstrated the good tolerability of bisoprolol fumarate. Other studies were either limited in number of patients or not randomized. However, these studies confirmed the good tolerability of bisoprolol in CHF patients, even in elderly population. Bisoprolol fumarate is a selective beta-1 receptor blocker that significantly reduced morbidity and mortality in stable CHF patients. Bisoprolol is well tolerated with few significant side effects in different large trials.

Show MeSH
Related in: MedlinePlus